查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468084

2024-2032 年霍亂疫苗市場報告（按疫苗類型、產品、最終用戶和地區分類）

Cholera Vaccines Market Report by Vaccine Type, Product, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球霍亂疫苗市場規模達540萬美元。公眾對霍亂預防的認知不斷提高、強力的政府舉措和國際合作、疫苗技術的不斷進步、旅行和貿易的激增、持續的研發活動以及對全球健康的重視是推動市場成長的一些因素。

霍亂疫苗是一種旨在預防霍亂的醫療干預措施，霍亂是一種導致腹瀉並可能導致脫水甚至死亡的細菌感染。它們是使用去活化或減毒的霍亂弧菌（霍亂病原體）組合開發的。這個過程涉及培養大量細菌，使它們無毒，然後將它們配製為疫苗。霍亂疫苗的優點是顯著的，例如它們提供了預防霍亂爆發的積極方法，特別是在衛生設施和供水不足的地區。透過增強免疫系統識別和對抗霍亂細菌的能力，這些疫苗可以減少疾病的嚴重程度和持續時間。此外，它們還有助於減少霍亂在社區內和跨國傳播。霍亂疫苗的兩種主要類型包括口服疫苗和注射疫苗。

全球霍亂疫苗市場受到霍亂預防意識不斷增強和疫苗接種重要性的影響，特別是在容易爆發疫情的地區。此外，政府措施和國際組織透過疫苗接種活動控制霍亂傳播的努力在市場擴張中發揮關鍵作用。此外，疫苗技術的進步導致開發出更有效率、更具成本效益的疫苗，從而促進了市場成長。此外，旅行和國際貿易頻率的增加促進了對霍亂疫苗接種的需求，因為旅行者可能會跨境攜帶這種疾病，這反過來又支持了市場的成長。除此之外，旨在提高疫苗功效和安全性的持續研發（R＆D）活動也有助於市場成長。

霍亂疫苗市場趨勢/促進因素：

提高認知與預防霍亂

人們對霍亂預防的認知不斷提高以及疫苗接種的關鍵作用，對全球霍亂疫苗市場產生了重大推動力。隨著社區越來越了解霍亂疫情的破壞性影響，對包括疫苗接種在內的有效預防措施的需求也隨之增加。這種認知的提高往往是由公共衛生運動、教育舉措和媒體報道推動的，這些運動、教育舉措和媒體報道強調了霍亂的後果以及疫苗接種在遏制其傳播方面的重要性。這個促進因素不僅激發了個人和社區對疫苗接種的興趣，也鼓勵政府、醫療保健組織和國際機構為疫苗接種活動分配資源，推動市場成長。

政府措施和國際努力

政府措施和國際組織的合作努力為全球霍亂疫苗市場的擴張做出了重大貢獻。霍亂高發地區政府意識到霍亂造成的社會經濟負擔，並將疫苗接種計畫作為重要的預防策略。此外，世界衛生組織（WHO）和聯合國兒童基金會等國際組織與各國政府建立夥伴關係，提供技術專業知識、資金和疫苗供應，以支持疫苗接種活動。這種協調一致的方法不僅確保了資源有限地區的疫苗可及性，而且透過創造對霍亂疫苗的穩定需求，為市場成長創造了有利的環境。

疫苗技術的進步

疫苗技術的進步在推動全球霍亂疫苗市場向前發展方面發揮關鍵作用。由於研發工作的重點是提高疫苗功效、安全性和生產流程，更新、更有效的霍亂疫苗被引入市場。這些進步使得疫苗能夠提供更持久的保護，需要更少的劑量，並且適合更廣泛的年齡層。此外，口服疫苗等疫苗輸送機制的創新有助於提高疫苗的接受度和管理的便利性，特別是在醫療基礎設施有限的地區。疫苗技術的不斷發展不僅提高了霍亂疫苗的整體有效性，還透過為醫療保健提供者和社區提供更好的疾病預防工具來推動市場成長。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球霍亂疫苗市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疫苗類型

  • 帶有重組 B 亞基的全細胞霍亂弧菌 O1
    • 市場走向
    • 市場預測
  • 殺死口服 O1 和 O139
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依產品

  • 杜科拉爾
    • 市場走向
    • 市場預測
  • 尚科爾
    • 市場走向
    • 市場預測
  • 瓦克斯喬拉
    • 市場走向
    • 市場預測
  • Euvichol 和 Euvichol-Plus
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院和診所
    • 市場走向
    • 市場預測
  • 研究和學術實驗室
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Astellas Pharma Inc.
    • Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
    • Emergent BioSolutions Inc.
    • Eubiologics Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Pfizer Inc.
    • PharmaChoice Canada Inc
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited.
    • Valneva SE
Product Code: SR112024A4973

The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032. The increasing public awareness of cholera prevention, robust government initiatives and international collaboration, continual advancements in vaccine technology, the surge in travel and trade, ongoing research and development activities, and the emphasis on global health are some of the factors fueling the market growth.

Cholera vaccines are medical interventions designed to provide protection against cholera, a bacterial infection that causes diarrhea and can lead to dehydration and even death. They are developed using a combination of inactivated or attenuated Vibrio cholerae bacteria, the causative agent of cholera. The process involves growing large quantities of the bacteria, rendering them non-virulent, and then formulating them into vaccines. The advantages of cholera vaccines are significant, such as they offer a proactive approach to preventing cholera outbreaks, particularly in regions with inadequate sanitation and water supplies. By bolstering the immune system's ability to recognize and fight the cholera bacteria, these vaccines can reduce the severity and duration of the illness. Moreover, they contribute to reducing the transmission of cholera within communities and across borders. Two main types of cholera vaccines include oral and injectable.

The global cholera vaccines market is influenced by the increasing awareness about cholera prevention and the importance of vaccination, especially in regions prone to outbreaks. Additionally, government initiatives and international organizations' efforts to control cholera's spread through vaccination campaigns play a pivotal role in market expansion. Moreover, advancements in vaccine technology, resulting in the development of more efficient and cost-effective vaccines, bolster market growth. Furthermore, the rising frequency of travel and international trade fosters the need for cholera vaccination, as travelers can potentially carry the disease across borders, which, in turn, is supporting the market growth. Besides this, ongoing research and development (R&D) activities aimed at enhancing vaccine efficacy and safety are contributing to the market growth.

Cholera Vaccines Market Trends/Drivers:

Increasing awareness and cholera prevention

The global cholera vaccines market experiences a significant impetus from the increasing awareness surrounding cholera prevention and the crucial role of vaccination. As communities become more informed about the devastating impact of cholera outbreaks, the demand for effective preventive measures, including vaccination, rises. This heightened awareness is often driven by public health campaigns, educational initiatives, and media coverage that highlight the consequences of cholera and the importance of vaccination in curbing its spread. This driver not only stimulates individual and community-level interest in vaccination but also encourages governments, healthcare organizations, and international bodies to allocate resources towards vaccination campaigns, propelling market growth.

Government initiatives and international efforts

Government initiatives and collaborative efforts by international organizations contribute significantly to the expansion of the global cholera vaccines market. Governments of cholera-prone regions recognize the socio-economic burden posed by cholera and prioritize vaccination programs as a crucial preventive strategy. Moreover, international organizations like the World Health Organization (WHO) and UNICEF engage in partnerships with governments, providing technical expertise, funding, and vaccine supply to support vaccination campaigns. This coordinated approach not only ensures vaccine accessibility in resource-constrained regions but also fosters a conducive environment for market growth by creating a steady demand for cholera vaccines.

Advancements in vaccine technology

Advancements in vaccine technology play a pivotal role in propelling the global cholera vaccines market forward. As research and development efforts focus on improving vaccine efficacy, safety, and production processes, newer and more effective cholera vaccines are introduced to the market. These advancements enable the creation of vaccines that offer longer-lasting protection, require fewer doses, and are suitable for a wider range of age groups. Additionally, innovations in vaccine delivery mechanisms, such as oral vaccines, contribute to increased vaccine acceptance and ease of administration, particularly in areas with limited healthcare infrastructure. The continuous evolution of vaccine technology not only enhances the overall effectiveness of cholera vaccines but also fuels market growth by providing healthcare providers and communities with better tools for disease prevention.

Cholera Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, product and end user.

Breakup by Vaccine Type:

Whole Cell V. Cholerae O1 with Recombinant B-Subunit

Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes whole cell V. cholerae O1 with recombinant B-subunit and killed oral O1 and O139. According to the report, whole cell V. cholerae O1 with recombinant B-subunit represented the largest segment.

The whole cell V. cholerae O1 with recombinant B-subunit segment is propelled by the comprehensive protection offered by whole-cell vaccines against cholera caused by V. cholerae O1. The inclusion of recombinant B-subunit enhances immunogenicity, bolstering the vaccine's efficacy in inducing protective immune responses. Additionally, the rising global awareness about cholera's impact on public health underscores the importance of advanced vaccines. Moreover, governmental initiatives and collaborations with international health organizations amplify the distribution and administration of these vaccines, especially in endemic regions. In line with this, ongoing research and development efforts continually refine vaccine formulations, ensuring optimal safety and effectiveness. Apart from this, the evolving landscape of international travel and trade heightens the demand for robust preventive measures, boosting the adoption of this segment.

Breakup by Product:

Dukoral

Shanchol

Vaxchora

Euvichol and Euvichol-Plus

Others

Dukoral dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes dukoral, shanchol, vaxchora, euvichol and euvichol-plus, and others. According to the report, dukoral represented the largest segment.

The dukoral segment is propelled by the surging awareness regarding the unique formulation of the product, encompassing both cholera and ETEC (enterotoxigenic Escherichia coli) antigens. Additionally, its established reputation for safety and efficacy, backed by rigorous clinical trials, instills confidence among healthcare professionals and recipients alike, boosting its adoption. Moreover, the expanding travel and tourism sector drives demand for dukoral, as it addresses the risk of cholera and ETEC infections associated with global mobility. Furthermore, its oral administration aligns with the preference for non-invasive vaccination methods, especially in regions with limited healthcare infrastructure. In line with this, ongoing research to refine dukoral's formulation and increase accessibility in underserved areas underscores its significance, solidifying its position as a driver in the market's growth trajectory.

Breakup by End User:

Hospitals and Clinics

Research and Academic Laboratories

Others

Hospitals and clinics dominate the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, research and academic laboratories, and others. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment dominates the market due to the increasing demand for quality healthcare services and medical interventions. Hospitals and clinics serve as primary access points for medical care, catering to a wide range of medical needs from routine check-ups to specialized treatments. Additionally, advancements in medical technology and treatments drive the need for modern and well-equipped healthcare facilities. Patients seek out hospitals and clinics that offer cutting-edge diagnostic and treatment options, thus encouraging the growth of this segment. Moreover, the growing aging population contributes significantly to the demand for healthcare services. As elderly individuals require more frequent medical attention, hospitals and clinics play a crucial role in providing geriatric care. Furthermore, the rise in chronic diseases necessitates ongoing medical care and management, prompting a greater reliance on hospitals and clinics for continuous patient support.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The North American cholera vaccines market is stimulated by a solid healthcare framework and an emphasis on disease prevention, with stringent public health policies and high awareness increasing demand. International travel and trade further necessitate vaccination. In Asia Pacific, rising cholera outbreaks, lack of sanitation, government efforts, population density, and tourism focus attention on vaccination. Europe's market is propelled by strong healthcare systems and proactive disease surveillance, while travel and trade accentuate the requirement for vaccination. Latin America's growth is due to uneven access to sanitation and government campaigns. In the Middle East and Africa, erratic sanitation infrastructure and recurring cholera outbreaks necessitate vaccines, with governmental and international efforts addressing waterborne diseases.

Competitive Landscape:

The competitive landscape within the market for cholera vaccine is characterized by a dynamic interplay of various factors that shape the positioning of key players. Market participants engage in a multitude of strategies to gain a competitive edge, including product innovation, strategic collaborations, geographical expansion, and mergers and acquisitions. The quest to capture larger market shares and establish brand prominence drives companies to invest in research and development, aiming to offer novel solutions that cater to evolving consumer needs. Furthermore, the emphasis on customer-centric approaches and effective marketing strategies is pivotal in differentiating brands in a crowded marketplace. Regulatory compliance and adherence to industry standards also contribute to the competitive dynamics. The competitive landscape is ever evolving, with players continuously adapting to market trends, customer preferences, and technological advancements to maintain their relevance and sustain growth in this competitive arena.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Astellas Pharma Inc.

Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)

Emergent BioSolutions Inc.

Eubiologics Co. Ltd.

Johnson & Johnson

Merck & Co. Inc.

Pfizer Inc.

PharmaChoice Canada Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Valneva SE

Recent Developments:

In June 2022, Sanofi unveiled the initiation of its first Digital Accelerator, a significant step that aligns with its aspiration to evolve into a top-tier digital healthcare company.

Key Questions Answered in This Report

  • 1. What was the size of the global cholera vaccines market in 2023?
  • 2. What is the expected growth rate of the global cholera vaccines market during 2024-2032?
  • 3. What are the key factors driving the global cholera vaccines market?
  • 4. What has been the impact of COVID-19 on the global cholera vaccines market?
  • 5. What is the breakup of the global cholera vaccines market based on the vaccine type?
  • 6. What is the breakup of the global cholera vaccines market based on the product?
  • 7. What is the breakup of the global cholera vaccines market based on the end user?
  • 8. What are the key regions in the global cholera vaccines market?
  • 9. Who are the key players/companies in the global cholera vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cholera Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Killed Oral O1 and O139
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Dukoral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Shanchol
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Vaxchora
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Euvichol and Euvichol-Plus
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research and Academic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Emergent BioSolutions Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eubiologics Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 PharmaChoice Canada Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Valneva SE
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials

List of Figures

  • Figure 1: Global: Cholera Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cholera Vaccines Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Cholera Vaccines Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Cholera Vaccines Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Cholera Vaccines Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Cholera Vaccines Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Cholera Vaccines (Killed Oral O1 and O139) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cholera Vaccines (Killed Oral O1 and O139) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cholera Vaccines (Dukoral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cholera Vaccines (Dukoral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cholera Vaccines (Shanchol) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cholera Vaccines (Shanchol) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cholera Vaccines (Vaxchora) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cholera Vaccines (Vaxchora) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cholera Vaccines (Other Product) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cholera Vaccines (Other Product) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cholera Vaccines (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cholera Vaccines (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cholera Vaccines (Research and Academic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cholera Vaccines (Research and Academic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Cholera Vaccines (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Cholera Vaccines (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Cholera Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Cholera Vaccines Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Cholera Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Cholera Vaccines Industry: SWOT Analysis
  • Figure 78: Global: Cholera Vaccines Industry: Value Chain Analysis
  • Figure 79: Global: Cholera Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cholera Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cholera Vaccines Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Cholera Vaccines Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Cholera Vaccines Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Cholera Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cholera Vaccines Market: Competitive Structure
  • Table 7: Global: Cholera Vaccines Market: Key Players